The Big4Bio Podcast shares podcasts that give insight and information about/from biotech and life science leaders and organizations within the Big4Bio regions. Check out our Playlists to hear podcasts by region.
Trial design, recruitment, and supply chains represent pain points that routinely derail timelines and budgets for sponsors. There are, however, ways that emerging biotechs can get more speed, rigor, and strategic value from their relationships with clinical contract research organizations. REV Clinical uses rigorous upfront feasibility, pre qualified high performing sites, and real time data oversight to enable faster study start up without sacrificing quality. Fairooz Kabbinavar, Chief Medical Officer at REV Clinical, offers advice on where lean biotechs should never cut corners, how to spot red flags in prospective CRO partners, and why “follow the science” remains the best operating principle when capital is scarce but expectations from regulators and investors keep rising.
25 Feb 2026
Every Moment Matters: Developing an N-of-1 ASO for a Child with an Ultra-Rare Disease
Advances in sequencing, the emergence of antisense oligonucleotide therapies, and the advent of induced pluripotent stem cell technology are among the combination of factors that have made bespoke medicines for individual patients scientifically feasible. In the case of ultra-rare, genetic diseases, a child may face a progressive, life-threatening condition with no available treatments. As we continue our series on discovery with Charles River Laboratories, we take a look at how the organization partnered with global collaborators and a patient’s family to design, screen, and advance a highly selective antisense oligonucleotide therapy targeting a pathogenic allele underlying a child’s ultra-rare epileptic encephalopathy. We spoke to Charles River Lab’s Associate Research Leader Blanca Torroba and Group Leader of Neuropharmacology Johanna Uhari Väänänen about how they moved from concept to a candidate for a custom ASO therapy, steps they took to accelerate the process, and the challenges of advancing N of 1 medicines to an IND.nbRb
18 Feb 2026
Every Moment Matters: A Case for Adaptive Immunogenicity Testing
Immunogenicity testing helps establish the safety of experimental therapies by ensuring drugs don’t trigger a potentially dangerous immune response. While regulators had long relied on a fixed, three-tier immunogenicity testing model, the industry is now shifting to a flexible, risk-based approach that continues to meet regulatory requirements and ensure patient safety. We spoke to Katie Sime, principal research scientist at Charles River Laboratories, about when reduced-tier approaches make sense, what regulators want to see; and why adaptive strategies can particularly benefit resource-constrained biotechs by balancing scientific rigor, patient safety, and budget constraints.
Who has been a guest on The Big4Bio Podcast
Names identified in recent episode analyses. Showing up to five guests.
Tim Scott
Mike Milligan
Gregg Beloff
Contact The Big4Bio Podcast
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of The Big4Bio Podcast?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
